FARAN SA and NOVARTIS (Hellas) SA are pleased to announce the launch of their collaboration in the field of therapeutic oncology. More specifically, FARAN undertakes the promotion and distribution in the Greek market of the NOVARTIS products TYVERB (Lapatinib) and ZYKADIA (Ceritinib). TYVERB (Lapatinib) is indicated for the treatment of patients with metastatic breast cancer whose tumors over-expresses HER2, while ZYKADIA (Ceritinib) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
This collaboration will strengthen FARAN's leading position in oncology setting among Greek companies, as NOVARTIS is a global leader in research, development and production of innovative drugs. So, FARAN remaining committed to her vision and values, continues to expand its collaboration with esteemed Multinational Pharmaceutical Companies, offering to the Greek patient and health care system, innovative products of High Quality and Therapeutic Value, for the treatment of serious illnesses.